CHAPLIN PAUL,PAUL CHAPLIN,SUTER MARK,MARK SUTER,ACKERMANN MATHIAS,MATHIAS ACKERMANN,FRANCHINI MARCO,MARCO FRANCHINI,VOLLSTEDT SABINE,SABINE VOLLSTEDT,HEFTI HANS PETER,HANS PETER HEFTI
申请号：
PL371594
公开号：
PL220781B1
申请日:
2003.04.16
申请国别(地区):
PL
年份:
2016
代理人:
摘要：
The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.
